Godrej Agrovet Reports Strong FY26 Results, Targets Double-Digit Growth

Godrej Agrovet has reported strong financial results for the fiscal year 2026, with consolidated revenue reaching ₹10,233 crore, a 9% increase year-on-year. Profit Before Tax (PBT), excluding exceptional items, grew 17.2% to ₹569 crore for the full year. For the fourth quarter, revenue climbed 9% to ₹2,333 crore, and PBT rose 16.8% to ₹87 crore. The company is optimistic about FY27, forecasting early double-digit revenue growth and mid-teens PBT growth, driven by strategic business evolution.

Key Business Strategy Shifts

The company's strategy is evolving across key segments. In Animal Nutrition, the focus is shifting from basic feed to comprehensive nutrition solutions. The Crop Care division is expanding with new product launches. The Oil Palm business is transforming from a basic volume producer to a fully integrated operation offering value-added products. These changes aim to boost profitability and create a more stable business.

Investment Plans for Growth

Godrej Agrovet plans to invest approximately ₹400 crore in capital expenditure for FY27. Around 75-80% of this will be allocated to growth initiatives. The company anticipates maintaining a cash surplus of ₹100-125 crore even after these investments.

Potential Risks

Investors should be aware of potential risks. Global factors like geopolitical tensions could affect commodity prices. Palm oil price volatility, linked to crude oil, remains a concern. A potential risk includes below-normal monsoons impacting the Crop Care segment. Additionally, Creamline Dairy is facing profitability challenges due to higher milk procurement costs.

Industry Comparison

In terms of scale, Godrej Agrovet's FY26 revenue of ₹10,233 crore positions it significantly above Dhanuka Agritech (approx. ₹1,600 Cr FY24 revenue) and PI Industries (approx. ₹7,000 Cr FY24 revenue), but it is smaller than UPL Ltd (approx. ₹52,000 Cr FY24 revenue). The company's PBT growth of 17.2% for FY26 is strong. While PI Industries benefits from its strong Contract Development and Manufacturing Organization (CDMO) segment, UPL has faced margin pressures.

What to Watch Next

Investors will closely monitor the impact of monsoons on the Crop Care segment and other vulnerable businesses. Progress on new product launches in Crop Care and their contribution to revenue growth will be a key indicator. Developments in the CDMO pipeline and the overall growth trajectory for subsidiary Astec LifeSciences will also be under watch. Tracking the increasing share of value-added products in the Oil Palm business will be crucial for assessing its resilience and potential profitability.